Athira Pharma (NASDAQ:ATHA) Stock Rating Lowered by Mizuho

Athira Pharma (NASDAQ:ATHA) was downgraded by Mizuho from an “outperform” rating to a “neutral” rating in a report issued on Thursday, Marketbeat Ratings reports. They presently have a $0.50 target price on the stock, down from their previous target price of $5.00. Mizuho’s price objective suggests a potential upside of 16.20% from the company’s current price.

Several other research firms have also weighed in on ATHA. Rodman & Renshaw lowered Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. BTIG Research lowered Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. Finally, JMP Securities lowered Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th.

Athira Pharma Trading Down 7.4 %

NASDAQ:ATHA opened at $0.43 on Thursday. The firm has a market capitalization of $16.49 million, a price-to-earnings ratio of -0.14 and a beta of 2.90. Athira Pharma has a 1-year low of $0.43 and a 1-year high of $4.30. The business’s fifty day moving average price is $2.55 and its 200 day moving average price is $2.53.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.05. Equities analysts forecast that Athira Pharma will post -2.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Kelly A. Romano acquired 27,400 shares of the stock in a transaction dated Monday, June 24th. The shares were acquired at an average price of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares in the company, valued at approximately $195,330.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 8,829 shares of company stock valued at $5,033 in the last three months. Insiders own 19.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Rothschild Investment LLC acquired a new position in shares of Athira Pharma during the 2nd quarter valued at about $34,000. Private Advisor Group LLC bought a new stake in Athira Pharma during the 4th quarter valued at approximately $32,000. Mirador Capital Partners LP bought a new stake in Athira Pharma during the 1st quarter valued at approximately $57,000. XTX Topco Ltd bought a new stake in Athira Pharma during the 2nd quarter valued at approximately $60,000. Finally, Invst LLC bought a new stake in Athira Pharma during the 2nd quarter valued at approximately $68,000. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.